Drug Trial Radar · NCT02323191
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
221
Actual
Start
Jan 19, 2015
Primary completion
Aug 21, 2020
Study completion Aug 21, 2020
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1, open-label, multicenter, global study will evaluate the safety, pharmacokinetics, and activity of emactuzumab and atezolizumab administered in combination in participants with selected locally advanced or metastatic solid tumors that are not amenable to standard treatment. Participants who receive emactuzumab and atezolizumab will continue to receive study drug as long as they experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data, biopsy results (if available), and clinical status, or withdrawal of consent.
Conditions
- Solid Cancers
Interventions
AtezolizumabDrug
Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.
EmactuzumabDrug
Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Dose Limiting Toxicities (DLTs)Time frame: 21 days
- Maximum Tolerated Dose (MTD) of EmactuzumabTime frame: 21 days
- Percentage of Participants With Adverse Events (AEs)Time frame: Baseline up to 3 years
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
Yale Cancer Center; Medical Oncology
New Haven, Connecticut
Massachusetts General Hospital.
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber - Harvard
Boston, Massachusetts
Memorial Sloan-Kettering Cancer Center Breast & Imaging Center
New York, New York
Cliniques Universitaires St-Luc
Brussels, Belgium
Centre Leon Berard; Departement Oncologie Medicale
Lyon, France
Institut Claudius Regaud; Departement Oncologie Medicale
Toulouse, France
Institut Gustave Roussy; Departement Oncologie Medicale
Villejuif, France
Hospital del Mar; Servicio de Oncologia
Barcelona, Spain
Centro Integral Oncológico Clara Campal Ensayos Clínicos START
Madrid, Spain
Clinica Universitaria de Navarra; Servicio de Oncologia
Pamplona, Navarre, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.